Compare ULCC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | CMPS |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2020 |
| Metric | ULCC | CMPS |
|---|---|---|
| Price | $7.09 | $12.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $5.21 | ★ $25.38 |
| AVG Volume (30 Days) | ★ 4.5M | 3.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,724,000,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $11.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.02 | $2.25 |
| 52 Week High | $7.11 | $14.76 |
| Indicator | ULCC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 70.18 | 58.33 |
| Support Level | $4.58 | $5.48 |
| Resistance Level | N/A | $14.76 |
| Average True Range (ATR) | 0.44 | 0.98 |
| MACD | 0.06 | -0.16 |
| Stochastic Oscillator | 91.51 | 43.26 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos, and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. The majority of revenue is from Domestic flight follow by International.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.